Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 20/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.93 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.93 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.82 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.74 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1722628 | 0.96 | ALOX5AP (1.00) | ALOX5APCYP3A4CYP2C9PTGS1ALOX5 | |
| SCHEMBL3067835 | 0.94 | ALOX5AP (0.93) | ALOX5APCYP3A4CYP2C9PTGS1ALOX5 | |
| SCHEMBL176032 | 0.92 | ALOX5AP (1.00) | ALOX5APCYP3A4CYP2C9PTGS1ALOX5 | |
| SCHEMBL170170 | 0.91 | ALOX5AP (1.00) | ALOX5APCYP3A4CYP2C9PTGS1ALOX5 | |
| SCHEMBL3062917 | 0.91 | ALOX5AP (0.86) | ALOX5APCYP3A4CYP2C9PTGS1ALOX5 | |
| SCHEMBL169386 | 0.90 | ALOX5AP (1.00) | ALOX5APCYP3A4CYP2C9PTGS1 | |
| SCHEMBL167756 | 0.90 | ALOX5AP (0.89) | ALOX5APCYP3A4CYP2C9PTGS1ALOX5 | |
| SCHEMBL170175 | 0.89 | ALOX5AP (0.85) | ALOX5APCYP3A4CYP2C9PTGS1ALOX5 | |
| SCHEMBL1255079 | 0.88 | ALOX5AP (0.85) | ALOX5APCYP3A4CYP2C9PTGS1ALOX5 | |
| SCHEMBL175962 | 0.88 | ALOX5AP (0.83) | ALOX5APCYP3A4CYP2C9PTGS1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100068301-A1 | COMPOSITIONS AND TREATMENTS COMPRISING 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS AND NITRIC OXIDE MODULATORS | PANMIRA PHARMACEUTICALS, LLC | 2010-03-18 | — | — | US | disclosed |
| US-20100068301-A1 | COMPOSITIONS AND TREATMENTS COMPRISING 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS AND NITRIC OXIDE MODULATORS | PANMIRA PHARMACEUTICALS, LLC | 2010-03-18 | — | — | US | disclosed |
| US-20100068301-A1 | COMPOSITIONS AND TREATMENTS COMPRISING 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS AND NITRIC OXIDE MODULATORS | PANMIRA PHARMACEUTICALS, LLC | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068301-A1 | COMPOSITIONS AND TREATMENTS COMPRISING 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS AND NITRIC OXIDE MODULATORS | ALOX5, ALOX15B, PTGIS | ALOX5AP 5/4885CYP3A4 1011/4885CYP2C9 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.